Navigation Links
UCLA bioengineers discover how particles self-assemble in flowing fluids
Date:12/13/2010

From atomic crystals to spiral galaxies, self-assembly is ubiquitous in nature. In biological processes, self-assembly at the molecular level is particularly prevalent.

Phospholipids, for example, will self-assemble into a bilayer to form a cell membrane, and actin, a protein that supports and shapes a cell's structure, continuously self-assembles and disassembles during cell movement.

Bioengineers at the UCLA Henry Samueli School of Engineering and Applied Science have been exploring a unique phenomenon whereby randomly dispersed microparticles self-assemble into a highly organized structure as they flow through microscale channels.

This self-assembly behavior was unexpected, the researchers said, for such a simple system containing only particles, fluid and a conduit through which these elements flow. The particles formed lattice-like structures due to a unique combination of hydrodynamic interactions.

The research, published online today in the journal Proceedings of the National Academy of Sciences, was led by UCLA postdoctoral scholar Wonhee Lee and UCLA assistant professor of bioengineering Dino Di Carlo.

The research team discovered the mechanism that leads to this self-assembly behavior through a series of careful experiments and numerical simulations. They found that continuous disturbance of the fluid induced by each flowing and rotating particle drives neighboring particles away, while migration of particles to localized streams due to the momentum of the fluid acts to stabilize the spacing between particles at a finite distance. In essence, the combination of repulsion and localization leads to an organized structure.

Once they understood the mechanism, the team developed microchannels that allowed for "tuning" of the spatial frequency of particles within an organized particle train. They found that by simply adding short regions of expanded channel width, the particles could be induced to self-assemble into different structures in a controllable and potentially programmable way.

"Programmable control of flowing microscale particles may be important in opening up new capabilities in biomedicine, materials synthesis and computation, similar to how improved control of flowing electrons has enabled a revolution in computing and communication," Di Carlo said.

For example, controlling the positions of microscale bioparticles, such as cells in flowing channels, is important for the operation of blood analysis and counting diagnostic systems. In addition, improving the uniformity of cell concentrations entering the microscale volume of a print head can enable burgeoning fields such as "tissue printing," in which single cells in a polymer ink are sequentially positioned to form a functional tissue architecture, such as the cylindrical lumen of a blood vessel.

More complete control of lattices of particles may also allow tunable manufacturing of optical or acoustic metamaterials that interact uniquely with light and sound waves based on the arrangement of the embedded particles, the researchers said.


'/>"/>

Contact: Matthew Chin
mchin@support.ucla.edu
310-206-0680
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. UC San Diego bioengineers fill holes in science of cellular self-organization
2. New method developed by UC San Diego bioengineers gives regenerative medicine a boost
3. Bioengineers succeed in producing plastic without the use of fossil fuels
4. Penn bioengineers create simulator to test blood platelets in virtual heart attacks
5. Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues
6. Formula discovered for longer plant life
7. Chemical equator discovery will aid pollution mapping
8. Researchers discover that growing up too fast may mean dying young in honey bees
9. Scientists discover why a mothers high-fat diet contributes to obesity in her children
10. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
11. Groundbreaking discovery may lead to stronger antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT Tandem Meetings of ... International Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 ... combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
(Date:2/16/2017)... Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... find a better treatment for triple negative breast cancer (TNBC), ... France program. The YEi Start ... designed to help entrepreneurs grow their business in ... eight American companies selected to complete an intensive one week ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
Breaking Biology Technology: